S&P 500   3,623.63 (-0.32%)
DOW   29,867.15 (-0.60%)
QQQ   295.60 (+0.38%)
AAPL   116.23 (+0.92%)
MSFT   213.63 (-0.11%)
FB   274.61 (-0.83%)
GOOGL   1,758.91 (-0.28%)
AMZN   3,184.31 (+2.12%)
TSLA   563.68 (+1.49%)
NVDA   528.90 (+2.04%)
BABA   277.37 (-0.93%)
CGC   26.88 (-0.33%)
GE   10.50 (+0.48%)
MU   63.00 (-1.49%)
AMD   86.48 (+1.66%)
T   28.98 (-0.86%)
NIO   53.17 (-0.64%)
F   9.15 (-3.17%)
ACB   8.62 (-6.61%)
NFLX   481.86 (-0.21%)
GILD   59.62 (-1.05%)
BA   217.86 (-0.29%)
DIS   147.94 (-2.34%)
S&P 500   3,623.63 (-0.32%)
DOW   29,867.15 (-0.60%)
QQQ   295.60 (+0.38%)
AAPL   116.23 (+0.92%)
MSFT   213.63 (-0.11%)
FB   274.61 (-0.83%)
GOOGL   1,758.91 (-0.28%)
AMZN   3,184.31 (+2.12%)
TSLA   563.68 (+1.49%)
NVDA   528.90 (+2.04%)
BABA   277.37 (-0.93%)
CGC   26.88 (-0.33%)
GE   10.50 (+0.48%)
MU   63.00 (-1.49%)
AMD   86.48 (+1.66%)
T   28.98 (-0.86%)
NIO   53.17 (-0.64%)
F   9.15 (-3.17%)
ACB   8.62 (-6.61%)
NFLX   481.86 (-0.21%)
GILD   59.62 (-1.05%)
BA   217.86 (-0.29%)
DIS   147.94 (-2.34%)
S&P 500   3,623.63 (-0.32%)
DOW   29,867.15 (-0.60%)
QQQ   295.60 (+0.38%)
AAPL   116.23 (+0.92%)
MSFT   213.63 (-0.11%)
FB   274.61 (-0.83%)
GOOGL   1,758.91 (-0.28%)
AMZN   3,184.31 (+2.12%)
TSLA   563.68 (+1.49%)
NVDA   528.90 (+2.04%)
BABA   277.37 (-0.93%)
CGC   26.88 (-0.33%)
GE   10.50 (+0.48%)
MU   63.00 (-1.49%)
AMD   86.48 (+1.66%)
T   28.98 (-0.86%)
NIO   53.17 (-0.64%)
F   9.15 (-3.17%)
ACB   8.62 (-6.61%)
NFLX   481.86 (-0.21%)
GILD   59.62 (-1.05%)
BA   217.86 (-0.29%)
DIS   147.94 (-2.34%)
S&P 500   3,623.63 (-0.32%)
DOW   29,867.15 (-0.60%)
QQQ   295.60 (+0.38%)
AAPL   116.23 (+0.92%)
MSFT   213.63 (-0.11%)
FB   274.61 (-0.83%)
GOOGL   1,758.91 (-0.28%)
AMZN   3,184.31 (+2.12%)
TSLA   563.68 (+1.49%)
NVDA   528.90 (+2.04%)
BABA   277.37 (-0.93%)
CGC   26.88 (-0.33%)
GE   10.50 (+0.48%)
MU   63.00 (-1.49%)
AMD   86.48 (+1.66%)
T   28.98 (-0.86%)
NIO   53.17 (-0.64%)
F   9.15 (-3.17%)
ACB   8.62 (-6.61%)
NFLX   481.86 (-0.21%)
GILD   59.62 (-1.05%)
BA   217.86 (-0.29%)
DIS   147.94 (-2.34%)
Log in
NASDAQ:CDMO

Avid Bioservices Stock Forecast, Price & News

$8.80
-0.20 (-2.22 %)
(As of 11/25/2020 11:28 AM ET)
Add
Compare
Today's Range
$8.73
Now: $8.80▼
$8.92
50-Day Range
$7.25
MA: $8.18▼
$9.23
52-Week Range
$3.02
Now: $8.80▼
$9.37
Volume2,231 shs
Average Volume382,057 shs
Market Capitalization$498.11 million
P/E RatioN/A
Dividend YieldN/A
Beta2.32
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Read More
Avid Bioservices logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.6Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.14 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDMO
Previous Symbol
CUSIPN/A
CIK704562
Webwww.avidbio.com
Phone714-508-6100
Employees222

Debt

Debt-to-Equity RatioN/A
Current Ratio1.50
Quick Ratio1.24

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$59.70 million
Price / Sales8.34
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.74 per share
Price / Book11.89

Profitability

EPS (Most Recent Fiscal Year)($0.27)
Net Income$-10,470,000.00
Net Margins-3.68%
Return on Equity-5.57%
Return on Assets-2.43%

Miscellaneous

Outstanding Shares56,603,000
Market Cap$498.11 million
Next Earnings Date12/14/2020 (Estimated)
OptionableOptionable
$8.80
-0.20 (-2.22 %)
(As of 11/25/2020 11:28 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

How has Avid Bioservices' stock been impacted by COVID-19?

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDMO stock has increased by 95.1% and is now trading at $8.80.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Avid Bioservices?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Avid Bioservices.

What stocks does MarketBeat like better than Avid Bioservices?

Wall Street analysts have given Avid Bioservices a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Avid Bioservices wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Monday, December 14th 2020.
View our earnings forecast for Avid Bioservices.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) issued its quarterly earnings results on Tuesday, September, 1st. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.12. The biopharmaceutical company had revenue of $25.39 million for the quarter. Avid Bioservices had a negative return on equity of 5.57% and a negative net margin of 3.68%.
View Avid Bioservices' earnings history.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices's stock reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2021 After-Hours earnings guidance on Tuesday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $76-81 million, compared to the consensus revenue estimate of $78.96 million.

What price target have analysts set for CDMO?

4 brokerages have issued 12-month price objectives for Avid Bioservices' stock. Their forecasts range from $7.50 to $12.00. On average, they expect Avid Bioservices' share price to reach $9.63 in the next twelve months. This suggests a possible upside of 9.4% from the stock's current price.
View analysts' price targets for Avid Bioservices.

Who are some of Avid Bioservices' key competitors?

Some companies that are related to Avid Bioservices include Viela Bio (VIE), Myovant Sciences (MYOV), IGM Biosciences (IGMS), Zentalis Pharmaceuticals (ZNTL), Ironwood Pharmaceuticals (IRWD), Prestige Consumer Healthcare (PBH), Y-mAbs Therapeutics (YMAB), Cryoport (CYRX), Generation Bio (GBIO), Amarin (AMRN), Madrigal Pharmaceuticals (MDGL), Mersana Therapeutics (MRSN), Aurinia Pharmaceuticals (AUPH), Dicerna Pharmaceuticals (DRNA) and Trillium Therapeutics (TRIL).
View all competitors.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the following people:
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 47, Pay $488.87k)
  • Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 56, Pay $662.28k)
  • Mr. Nicholas Stewart Green, Pres, CEO & Director (Age 55)
  • Mr. Richard Richieri, Chief Operations Officer (Age 55)
  • Ms. Lorna Larson, Sr. Director of HR
  • Mr. Timothy Compton, Chief Commercial Officer
  • Dr. Shelley P. M. Fussey, VP of Intellectual Property (Age 54)
  • Ms. Tracy L. Kinjerski, VP of Bus. Operations
  • Mr. Harold F. Dvorak, Medical & Scientific Advisor
  • Prof. Alan J. Schroit, Medical & Scientific Advisor

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.77%), Iszo Capital Management LP (6.11%), Snyder Capital Management L P (4.07%), AltraVue Capital LLC (3.49%), State Street Corp (1.75%) and AWM Investment Company Inc. (1.40%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Mark R Ziebell, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends for Avid Bioservices.

Which major investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Iszo Capital Management LP, State Street Corp, JPMorgan Chase & Co., Quinn Opportunity Partners LLC, ClariVest Asset Management LLC, Morgan Stanley, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Avid Bioservices company stock in the last year include Daniel R Hart, and Mark R Ziebell.
View insider buying and selling activity for Avid Bioservices.

Which major investors are buying Avid Bioservices stock?

CDMO stock was purchased by a variety of institutional investors in the last quarter, including Punch & Associates Investment Management Inc., New York State Common Retirement Fund, Zebra Capital Management LLC, Trexquant Investment LP, AWM Investment Company Inc., Fisher Asset Management LLC, Schonfeld Strategic Advisors LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have bought Avid Bioservices stock in the last two years include Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Patrick D Walsh, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $8.80.

How big of a company is Avid Bioservices?

Avid Bioservices has a market capitalization of $498.11 million and generates $59.70 million in revenue each year. The biopharmaceutical company earns $-10,470,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Avid Bioservices employs 222 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is www.avidbio.com.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.